Calibr, A Division Of Scripps Research
Clinical trials sponsored by Calibr, A Division Of Scripps Research, explained in plain language.
-
New hope for pouchitis sufferers: experimental drug enters trial
Disease control TerminatedThis study tests an experimental drug called CLF065 in 20 adults with chronic pouchitis, a condition causing inflammation in a surgically created internal pouch. Participants receive weekly doses of CLF065 or a placebo to see if the drug safely reduces symptoms and inflammation. …
Phase: PHASE2 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Promising autoimmune therapy trial pulled before it even started
Disease control TerminatedThis study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
15-Year watch begins for gene therapy recipients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 40 people who previously received CLBR001, a gene-modified cell therapy, to monitor long-term safety over 15 years. No new treatment is given. Researchers will track side effects and check for any lingering virus from the gene therapy. The goal is to understand…
Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC